Biomarin Pharmaceutical (BMRN) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $59.1 million.
- Biomarin Pharmaceutical's Accumulated Depreciation & Amortization fell 1881.38% to $59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year decrease of 1881.38%. This contributed to the annual value of $96.4 million for FY2024, which is 762.55% down from last year.
- Per Biomarin Pharmaceutical's latest filing, its Accumulated Depreciation & Amortization stood at $59.1 million for Q3 2025, which was down 1881.38% from $40.6 million recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization registered a high of $108.0 million during Q4 2021, and its lowest value of $22.1 million during Q1 2025.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $55.2 million (2021), whereas its average is $61.3 million.
- In the last 5 years, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization skyrocketed by 788.2% in 2021 and then tumbled by 2449.41% in 2025.
- Quarter analysis of 5 years shows Biomarin Pharmaceutical's Accumulated Depreciation & Amortization stood at $108.0 million in 2021, then fell by 5.62% to $102.0 million in 2022, then increased by 2.37% to $104.4 million in 2023, then fell by 7.63% to $96.4 million in 2024, then plummeted by 38.69% to $59.1 million in 2025.
- Its last three reported values are $59.1 million in Q3 2025, $40.6 million for Q2 2025, and $22.1 million during Q1 2025.